DOCSLIB.ORG

Gastrointestinal (Colorectal and Anal)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gastrointestinal (Colorectal and Anal) GASTROINTESTINAL CANCER—COLORECTAL AND ANAL 3500 Oral Abstract Session Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Thierry Andre, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J. A. Punt, Denis Michel Smith, Rocio Garcia-Carbonero, Julia Alcaide, Peter Gibbs, Christelle De La Fouchardiere, Fernando Rivera, Elena Elez, Johanna C. Bendell, Dung T. Le, Takayuki Yoshino, Wen Yan Zhong, David R. Fogelman, Patricia Marinello, Luis A. Diaz; Sorbonne Universite� and Ho^pital- Saint Antoine, Paris, France; University College Hospital, NHS Foundation Trust, London, United King- dom; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Herlev and Gentofte Hospital, Herlev, Denmark; University Hospital of Southern Denmark, Vejle, Denmark; Depart- ment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, Netherlands; Bordeaux University Hospital, Bordeaux, France; Hospital Universitario 12 de Octubre, Imas12, CNIO, UCM, Madrid, Spain; Hospital Regional Universitario de Malaga, Ma�laga, Spain; Western Health, St. Al- bans, Australia; Centre Le�on Be�rard, Lyon, France; Hospital Universitario Marque�s de Valdecilla, IDIV- AL, Santander, Spain; Vall dHebron Institute of Oncology, Barcelona, Spain; Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; National Cancer Center Hospital East, Kashiwa, Japan; MSD China, Shanghai, China; Merck & Co., Inc., Kenilworth, NJ; Memorial Sloan Kettering Cancer Center, New York, NY Background: In the phase III, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pem- brolizumab (pembro) versus chemotherapy (chemo) provided superior progression-free survival (PFS) at second interim analysis (IA2) in patients (pts) with MSI-H/dMMR mCRC. The study continued to final analysis of overall survival (OS), planned after 190 OS events or 12 months after IA2, whichever oc- curred first. We present results of the final analysis of OS, 12 months after IA2. Methods: A total of 307 pts with MSI-H/dMMR mCRC and ECOG PS 0 or 1 were randomized 1:1 to 1L pembro 200 mg Q3W for up to 2y or investigator’s choice of mFOLFOX6 or FOLFIRI Q2W ± bevacizumab or cetuximab. Treat- ment continued until PD, unacceptable toxicity, pt/investigator decision to withdraw, or completion of 35 cycles (pembro only). Pts receiving chemo could crossover to pembro for up to 35 cycles after con- firmed PD. Primary end points were OS and PFS (RECIST v1.1, central review). Secondary end points included ORR, duration of response (DOR) (RECIST v1.1, central review), and safety. For OS signifi- cance, the p-value had to meet a prespecified a of 0.0246 (one-sided). Sensitivity analyses to adjust for crossover effect were performed. Data cut-off for final analysis was Feb 19, 2021. Results: Median (range) study follow-up was 44.5 mo (36.0-60.3) with pembro vs 44.4 mo (36.2-58.6) with chemo. 56 (36%) pts crossed over from chemo to pembro, with 37 more receiving anti-PD-1/PD-L1 therapies off study (60% effective crossover rate in the ITT). The HR for OS favored pembro vs chemo with a trend to- ward reduction in the risk of death (HR 0.74; 95% CI, 0.53-1.03; P=0.0359; median not reached [NR] vs 36.7 mo); this difference did not reach statistical significance. Sensitivity analysis by the rank- preserving structure failure time model and inverse probability of censoring weighting showed OS HRs of 0.66 (95% CI 0.42-1.04) and 0.77 (95% CI 0.44-1.38), respectively. Pembro vs chemo met the prespecified criteria for PFS superiority at IA2. At final analysis, median PFS was 16.5 mo vs 8.2 mo (HR 0.59; 95% CI, 0.45-0.79), but was not formally tested per analysis plan. Confirmed ORR was 45.1% (20 CR, 49 PR) vs 33.1% (6 CR, 45 PR). Median (range) DOR was NR (2.3+ to 53.5+) vs 10.6 mo (2.8 to 48.3+), respectively. Treatment-related adverse events (TRAEs) occurred in 79.7% vs 98.6% of pts; 21.6% vs 66.4%, respectively, had grade $3 TRAEs. Conclusions: As 1L therapy for pts with MSI-H/dMMR mCRC, pembro vs chemo provides statistically superior PFS with fewer TRAEs, and is associated with a trend toward reduced mortality that did not meet statistical significance likely due to the high crossover rate from chemo to anti-PD1/PD-L1 therapies. Together these data confirm pem- bro as a new standard-of-care in the 1L for pts with MSI-H/dMMR mCRC. Clinical trial information: NCT02563002. Research Sponsor: Merck & Co., Inc. © 2021 by American Society of Clinical Oncology. Visit abstracts.asco.org and search by abstract for disclosure information. GASTROINTESTINAL CANCER—COLORECTAL AND ANAL 3501 Oral Abstract Session The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13). Akihito Tsuji, Hisatsugu Ohori, Tatsuro Yamaguchi, Masato Matsuura, Atsujiro Nishioka, Akitaka Makiyama, Shingo Noura, Mitsugu Kochi, Tamotsu Sagawa, Masahito Kotaka, Yutaro Kubota, Yu Sunakawa, Takashi Sekikawa, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii; Department of Medical Oncology, Kagawa University Hospital, Takamatsu, Japan; Department of Medi- cal Oncology, Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Japan; Department of Surgery, To- kyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan; Department of Surgery, Kobe City Nishi-Kobe Medical Center, Kobe, Japan; Division of Hematology, Re- spiratory Medicine and Oncology, Saga University Hospital, Saga, Japan; Department of Hematology/ Oncology, Japan Community Healthcare Organization Kyushu Hospital, Kitakyushu, Japan; Department of Surgery, Toyonaka Municipal Hospital, Toyonaka, Japan; Department of Digestive Surgery, Nihon University Itabashi Hospital, Tokyo, Japan; Division of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan; Division of Medical Oncology, Showa University Hospital, Tokyo, Japan; Department of Clinical Oncolo- gy, St. Marianna University School of Medicine, Kawasaki, CA, Japan; Division of Clinical Oncology, De- partment of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan; Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan; Department of Clinical Medicine (Biostatistics), School of Pharmacy, Kitasato University, Tokyo, Japan; Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan; Department of Digestive Surgery, Nihon Uni- versity School of Medicine, Tokyo, Japan Background: Triplet regimens, FOLFOXIRI, combined with bevacizumab (bev) or panitumumab have been shown to be superior in terms of early tumor shrinkage (ETS) and depth of response (DpR) com- pared to doublet combinations in patients with RAS wild-type metastatic colorectal cancer (mCRC), in the TRIBE trial (N Engl J Med 2014) or the VOLFI trial (J Clin Oncol 2019), respectively. There have been few studies which directly compared cetuximab (cet) with bev when combined with triplet regi- men. Therefore, we investigated the efficacy and safety of bev vs. cet in combination with FOLFOXIRI in previously untreated mCRC patients with RAS wild-type tumors. Methods: This trial was a randomized phase II trial to evaluate modified (m)-FOLFOXIRI (irinotecan 150mg/m2, oxaliplatin 85mg/m2, 5-FU 2400mg/m2) plus cet vs. bev as first-line treatment in terms of DpR during the entire course as the pri- mary endpoint in 360 patients with RAS wild-type mCRC. The aim of the trial was to show that median DpR of cet arm was more than 12.5% higher than bev arm, with a power of 85% at a significance level of 0.05. Secondary endpoints included ETS rate at week 8, overall response rate (ORR), progression- free survival (PFS), overall survival (OS), secondary resection rate, and toxicity. Results: A total of 359 patients were enrolled between July 2015 and June 2019. For the full analysis set (median age 65y, 64% male, PS0/1: 91%/9%, left/right primary: 83%/17%), 173 and 175 patients were randomly as- signed to the cet and bev arms, respectively. On the cutoff date of September 2020, the median num- ber of cycles administered was 10 (range, 1-51) for the cet arm and 12 (range, 1-51) for the bev arm. Safety data was already reported at the ASCO GI symposium 2021 (J Clin Oncol 39, 2021 suppl 3; abstr 86). The primary endpoint was met (p =.001); 57.4%（ -15.0~100） for the cet arm versus 46.0% （-0.6~100）for the bev arm. As for primary tumor sidedness, median DpR were 60.3% versus 46.1% (p =.0007) in the left-side and 50.0% versus 41.2% (p =.46) in the right-side. The ETS rate and ORR as the secondary endpoints were 77.8% and 69.1% in the cet arm versus 74.6% and 71.7% in the bev arm, respectively, with no statistical significance. Although the survival data were immature, PFS and OS of both arms were 12.7 months (95%CI 11.5-14.0) and 37.6 months (95%CI 30.8 to 43.0), respectively. Conclusion: The mFOLFOXIRI plus cet has been shown to be significantly superior to the mFOLFOXIRI plus bev in terms of DpR as the primary endpoint in first-line treatment for RAS wild-type mCRC. Clinical trial information: NCT02515734. Clinical trial information: UMIN000018217. Research Sponsor: Merck Biopharma Co., Ltd. © 2021 by American Society of Clinical Oncology. Visit abstracts.asco.org and search by abstract for disclosure information. GASTROINTESTINAL CANCER—COLORECTAL AND ANAL 3502 Oral Abstract Session Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first- line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).
Load more

Recommended publications
  • Decreased Serum Ceruloplasmin Levels Characteristically Aggravate Nigral Iron Deposition in Parkinson’S Disease Downloaded From
    doi:10.1093/brain/awq319 Brain 2011: 134; 50–58 | 50 BRAIN A JOURNAL OF NEUROLOGY Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson’s disease Downloaded from Lirong Jin,1,* Jian Wang,2,* Lei Zhao,1 Hang Jin,2 Guoqiang Fei,1 Yuwen Zhang,1 Mengsu Zeng2 and Chunjiu Zhong1,3,4 brain.oxfordjournals.org 1 Department of Neurology, Zhongshan Hospital and Shanghai Medical College, Fudan University, Shanghai, China 2 Department of Radiology, Zhongshan Hospital and Shanghai Medical College, Fudan University, Shanghia, China 3 State Key Laboratory of Medical Neurobiology, Shanghai Medical College, Fudan University, Shanghai, China 4 Institutes of Brain Science, Fudan University, Shanghai, China *These authors contributed equally to this work. Correspondence to: Chunjiu Zhong, MD, PhD, at Main Library L610 Lawrence Livermore Nat Lab on January 23, 2011 Department of Neurology, Zhongshan Hospital and Shanghai Medical College, Fudan University, Shanghai, China E-mail: [email protected] Correspondence may also be addressed to: Mengsu Zeng, MD, PhD, E-mail: [email protected] In vivo and post-mortem studies have demonstrated that increased nigral iron content in patients with Parkinson’s disease is a prominent pathophysiological feature. However, the mechanism and risk factors associated with nigral iron deposition in pa- tients with Parkinson’s disease have not been identified and represent a key challenge in understanding its pathogenesis and for its diagnosis. In this study, we assessed iron levels in patients with Parkinson’s disease and in age- and gender-matched control subjects by measuring phase values using magnetic resonance based susceptibility-weighted phase imaging in a 3T magnetic resonance system.
    [Show full text]
  • Propaganda Fidei: Die Nantang-Kirche Und Die Jesuitischen Sakralräume Im Peking Der Frühen Neuzeit
    Inauguraldissertation zur Erlangung der Doktorwürde der Philosophischen Fakultät der Ruprecht-Karls-Universität Heidelberg, Institut für Kunstgeschichte Ostasiens Propaganda fidei: Die Nantang-Kirche und die jesuitischen Sakralräume im Peking der Frühen Neuzeit vorgelegt von Lianming Wang aus Zhejiang, VR China September 2014 Erstgutachter: Prof. Dr. Lothar Ledderose Zweitgutachterin: Prof. Dr. Melanie Trede Externe Betreuerin: Apl. Prof. Dr. Claudia von Collani (Würzburg) finanziert durch Geschwister Supp Stiftung (01.2010-12.2012) Exzellenzinitiative der Graduiertenakademie der Universität Heidelberg (10.2010) Ricci Institute for Chinese and Western Cultural History, University of San Francisco (03.2013) Heinz-Götze-Stiftung für Kunstgeschichte Chinas (07.2013; 03.2014) Inhaltsverzeichnis Einleitung Mission, Kunst und Globalität: Defizite und Konzeptionen…………………...................1 Forschungsgeschichte……………………………………………………………............15 Kapitel I: Stadt, Öffentlichkeit und der jesuitischer Urbanismus 1.1 Gründung der Mission in Peking, 1601-05………………………………….............20 Hintergrund……………………………………………………………………........21 Geschenk, Freundschaft und Netzwerk…………………………………….............22 1.2 Erwerb des Grundstücks, 1605……………………………………………...............24 1.3 Erschaffung eines Orientierungspunktes……………………………………............28 Das Xuanwu-Tor……………………………………………………………….......28 Bauplatz im Wandel der Zeit………………………………………………….........31 1.4 Stadt, Öffentlichkeit und die jesuitische „sakrale Strategie“………………..............33 Die topographische Tradition
    [Show full text]
  • China's Labor Question
    Christoph Scherrer (Ed.) China’s Labor Question Rainer Hampp Verlag München, Mering 2011 Bibliographic information published by the Deutsche Nationalbibliothek Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available in the Internet at http://dnb.d-nb.de. ISBN 978-3-86618-387-2 Picture on cover: Workers are seen inside a Foxconn factory in the township of Longhua in the southern Guangdong province May 26, 2010 (reproduced by permission of REUTERS/Bobby Yip) First published in 2011 © 2011 Rainer Hampp Verlag München, Mering Marktplatz 5 86415 Mering, Germany www.Hampp-Verlag.de All rights preserved. No part of this publication may be reprinted or reproduced or util- ized in any form or by any electronic, mechanical, or other means, now known or hereaf- ter invented, including photocopying and recording, or in any information storage or re- trieval system, without permission in writing from the publisher. In case of complaints please contact Rainer Hampp Verlag. TABLE OF CONTENTS Acknowledgements............................................................................................................. vi Notes on Contributors........................................................................................................ vii Introduction: The many Challenges of Chinese Labor Relations..................................1 Christoph Scherrer Part I: The Basic Setting 1. Perspectives on High Growth and Rising Inequality .......................................................7
    [Show full text]
  • The 2 Asia Medical Week
    SYNERGIZED INNOVATION & SUSTAINED EVOLUTION THE 2nd ASIA MEDICAL WEEK ASIAN MEDICAL INNOVATION & DEVELOPMENT FORUM 2019 Fudan Zhongshan International Oncology Summit & Annual Conference of Fudan Zhongshan Cancer Center Shanghai / Shenzhen Oct.19-21 2019 ACTIVITIES RECAP 2018 South Korea 2019 Statistics 11 4 4 1000+ 30 81% Sub-Forums Private Sessions Clinial Exchange Visit Attendees Countries & Regions Top Management Presidents, Vice-Presidents, CEOs, Directors or Officers from Governments, MOHs & Hospitals. Overseas Visitors Armenia Australia Bangladesh Belarus Brazil China Egypt France Greece India Indonesia Italy Japan Kazakhstan Kenya Malaysia Myanmar Northern Cyprus Pakistan Philippines Russia Singapore South Korea Sri Lanka Thailand Turkey Ukraine UK US Vietnam Launching Ceremony Dear Professors, We take a great pleasure in inviting you to the 2019 Asian Medical Week, which is held in Shanghai from October 19th to October 21st , 2019. Asia Medical Week is a prominent academic event for promoting medical communication and cooperation in the Asia-Pacific region. With the theme focusing on "Medical Innovation & Development", 2019 Asia Medical Week is dedicated to providing an effective communication platform for international healthcare community and industry to showcase China’s latest oncology, promote sharing for high-quality healthcare resources and advocate high-tech cooperation for modern medicine. Towards a vision of "Collaborative Innovation, Sustainable Progress", Fudan University Zhongshan Hospital and Fudan University Zhong Shan Hospital Cancer Center (FUZSCC) will host the 2019 Asian Medical Week - - Medical Innovation & Development Forum, featuring 2019 Fudan Zhongshan International Oncology Summit, in concurrent with the annual meeting of FUZSCC. To pace the internationalization and development of China healthcare system through in-depth communication and collaboration between Asia-Pacific countries, the program will focus on the newest advances in tumor management and establish “the Belt and Road” Oncology Alliance during the event.
    [Show full text]
  • Enhanced Activities of Blood Thiamine Diphosphatase and Monophosphatase in Alzheimer’S Disease
    RESEARCH ARTICLE Enhanced Activities of Blood Thiamine Diphosphatase and Monophosphatase in Alzheimer's Disease Xiaoli Pan1,2☯, Shaoming Sang1,2☯, Guoqiang Fei1, Lirong Jin1, Huimin Liu2, Zhiliang Wang3, Hui Wang3, Chunjiu Zhong1,2* 1 Department of Neurology, Zhongshan Hospital & Shanghai Medical College, Fudan University, Shanghai, China, 2 State Key Laboratory of Medical Neurobiology, Institutes of Brain Science & Collaborative Innovation Center for Brain Science, Fudan University, Shanghai, China, 3 Regional Health Service Center of a11111 Xujiahui, Xuhui District, Shanghai, China ☯ These authors contributed equally to this work. * [email protected] Abstract OPEN ACCESS Citation: Pan X, Sang S, Fei G, Jin L, Liu H, Wang Z, et al. (2017) Enhanced Activities of Blood Background Thiamine Diphosphatase and Monophosphatase in Thiamine metabolites and activities of thiamine-dependent enzymes are impaired in Alzhei- Alzheimer's Disease. PLoS ONE 12(1): e0167273. mer's disease (AD). doi:10.1371/journal.pone.0167273 Editor: Marie-Claude Potier, Institut du cerveau et de la moelle epiniere, FRANCE Objective Received: April 17, 2016 To clarify the mechanism for the reduction of thiamine diphosphate (TDP), an active form of Accepted: November 12, 2016 thiamine and critical coenzyme of glucose metabolism, in AD. Published: January 6, 2017 Copyright: © 2017 Pan et al. This is an open access Methods article distributed under the terms of the Creative Forty-five AD patients clinically diagnosed and 38 age- and gender-matched control sub- Commons Attribution License, which permits unrestricted use, distribution, and reproduction in jects without dementia were voluntarily recruited. The contents of blood TDP, thiamine any medium, provided the original author and monophosphate (TMP), and thiamine, as well as the activities of thiamine diphosphatase source are credited.
    [Show full text]
  • International Students Guide Book Siping Campus English Version 1.Bank of Communication(交通银行) Add：41 Zhangwu Rd
    International Students Guide Book Siping Campus English Version 1 International Students Guide Book Siping Campus English Version Foreword Hello! Welcome to Tongji University! We wrote this guide book for you to help you with your life on campus and even in Shanghai. It contains some useful information that you may need in your study and daily life. Hope it can really do some help and wish you enjoy your life here! Group member： Ding Weiling (School of Political Science & International Relations) Dai Haocheng (College of Electronics & Information Engineering) Yu Zhenghao (College of Design & Innovation) Zhang Pei (Law school) April. 2017 2 International Students Guide Book Siping Campus English Version Contents First Arrived in Shanghai Overview of Shanghai 6 Overview of Tongji University 6 Legal Residence 7 Campus Life Student ID Card 15 Study 17 Dining 23 Medical Care 25 Network Communication 27 Traffic 30 Sports 32 School Stores & Shops 34 Activities 35 Useful Apps 36 Around the Campus Public Transportation 39 Banking 43 Shopping & Recreation 45 Campus Map 48 3 International Students Guide Book Siping Campus English Version Contents for Important Pictures Temporary Accommodation 13 Pharmacy around the Campus 27 Metro Stations around the Campus 40 Shanghai Metro Map 41 Bus Stations around the Campus 42 Banks & ATMs around the Campus 44 Campus Map 48 4 International Students Guide Book Siping Campus English Version First Arrived in Shanghai Overview of Shanghai 6 Overview of Tongji University 6 Legal Residence 7 5 International Students Guide Book Siping Campus English Version Overview of Shanghai Shanghai, once a humble fishing village, is now the economic, financial, trade and shipping center of China.
    [Show full text]
  • Cross-Culture Research for Developing WHO Self-Assessment
    Cross-Culture Research for Developing (Chinese version) WHO Self-Assessment tool for Health Promotion in Hospital Objectives Through cross-culture research to develop a Chinese version WHO self-assessment tool for Health Promotion in Hospital; Explore a high effective health care service model through developing health promotion in hospital; Discuss the strategies for HPH development in undeveloped region. Context Why the different conditions and resources makes the similar health promotion result between China and U.S Total expenditure on health per 83 The Unite State capita (Intl $, WHO,2006) Canada 6714 80 China 78 75 75 3672 72 342 Female Male The Unite Canada China Life expectancy at State birth(years) What are the differences between China and Unite State for developing HPH China The Unite State 1. Poor HPH condition Excellent HPH condition and and resource resource 2. Poor medical service Advanced medical service management system management system 3. Serious shortage of Excellent health service health service resource support system and resource 4. Poor public health developing condition Advanced public health and resource developing condition and resource What are the different HPH developing conditions between China and the Unite State China The Unite State Developed Country 1. Undeveloped country, Gross national income Gross national income per per capita (PPP capita (PPP international international $): 4,660 $): 44,070 2. 1.3billion population 0.3billion population 3. Polluted environment Healthy environment The different
    [Show full text]
  • Shanghai Guide
    “YOUR NAME HERE” …and your logo here. We hope you find this guide useful. If you wish to put your company’s name on it and publish we have a number of options for you. Please contact us at [email protected] “Committed to making you feel at home” Shanghai Guide For any specific information or enquires, please contact us Your address here E-mail: [email protected] Website: http://www.wwwaldron.com “YOUR NAME HERE” CONTACT [email protected] FOR MORE INFO. Welcome to Shanghai “YOUR NAME HERE” extends its most sincere welcome to you and to the members of your family who may be accompanying you on your assignment to Shanghai. Leaving home, family and friends behind to move to a new and perhaps completely unfamiliar place can be a difficult experience. It can however, be an exciting and rewarding time - new experiences and acquaintances await you. We in “YOUR NAME HERE” are here to guide and assist you through each and every step of your relocation to ensure a smooth transition to the new life that awaits you in Shanghai. This Relocation Guidebook has been developed as a useful and informative tool to provide answers to many of the questions that you and your family may have as you begin the resettlement process. We have included different sections including topics like housing, medicals, schools, transportation, etc. We have also included many places for food and drink, recreation, shopping, and weekend activities. This guidebook has been carefully prepared to give you all the information and more that you may ever need to help you settle into the Shanghai way of life.
    [Show full text]
  • Famous Hospitals in Shanghai City
    Famous Hospitals in Shanghai City Franco Naccarella Medical service system and pertinent bureau • There are four medical service systems in Shanghai. • They are Fu Dan University, Shanghai Jiao Tong University, Tong Jing University, Shanghai Traditional Chinese Medical School • Shanghai Bureau of health make the rule of hearth care and supervise all the hospitals attached to their university. Top Ten Hospital Fudan University • Zhongshan Hospital • Huashan Hospital Shanghai Jiao Tong University • First People’s Hospital • Sixth People’s Hospital • Renji Hospital • Ruijin Hospital • Xinhua Hospital • Nineth People’s Hospital Second Military Medical University • Changhai Hospital • Changzheng Hospital Zhongshan hospital Zhongshan hospital • Zhongshan Hospital was founded in 1936 in commemoration of the late Dr. Sun Yat- sen. It is a leading hospital in China and was awarded "The Best 100 Hospitals" in 1999 • The discipline of Zhongshan Hospital is Prudent, Practicality, Unity and Offering Zhongshan hospital www.zs-hospital.sh.cn • Cardiology, Hepatology,Nephrology and Respiratory diseases are their leading subject • Cardiology research institute is well known in the world. They performed the first cardiac catheter examination in China Zhongshan hospital • Cardiology department is the largest in Shanghai area. They have three catheter room, non-invasive cardiac exam center including treadmill exercise test, tilt table test, holter monitor, ABPM and advanced Echo center. • EP center have sophisticated EP console. They own CARTO-XP 3 dimension electroanatomy mapping equipment Zhongshan hospital • Their emergency PCI number is the largest in Shanghai area, about 400 cases for one year, and more than 1000 cases of selective PCI cases every year • The cardiolog department is also well known for myocardiopathy and myocarditis research • They are number of national qualified clinical medicine trial base and national EP training base Zhongshan hospital • The chief of cardiolgy is prof.
    [Show full text]
  • A Time-Series Panel Study
    Science of the Total Environment 619–620 (2018) 360–365 Contents lists available at ScienceDirect Science of the Total Environment journal homepage: www.elsevier.com/locate/scitotenv Effects of ambient temperature on lung function in patients with chronic obstructive pulmonary disease: A time-series panel study Zhijing Lin a,1, Yutong Gu b,1,CongLiua,YuanlinSongb, Chunxue Bai b,RenjieChena,c,⁎, Shujing Chen b,⁎⁎,HaidongKana a School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and Key Lab of Health Technology Assessment of the Ministry of Health, Fudan University, Shanghai 200032, China b Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China c Shanghai Key Laboratory of Meteorology and Health, Shanghai 200030, China HIGHLIGHTS GRAPHICAL ABSTRACT • This is a time-series panel study with in- tensive daily lung function measure- ments. • The associations between daily temper- ature and PEF were inverted U–shaped. • Both low and high temperatures were significantly associated with reduced PEF. • No apparent associations were observed for temperature and FEV1. article info abstract Article history: Background: Limited evidence concerns the associations between ambient temperature and lung function and Received 27 April 2017 the results are mixed. Received in revised form 3 November 2017 Objective: To evaluate the associations between temperature variations and daily fluctuations in pulmonary func- Accepted 3 November 2017 tion in chronic obstructive pulmonary disease (COPD) patients. Available online xxxx Methods: We designed a time-series panel study of 28 male urban COPD patients with repeated daily lung func- tion measurements from December 2012 to May 2013 in Shanghai, China.
    [Show full text]
  • Surgical Fixation of Rib Fractures Decreases Intensive Care Length of Stay in Flail Chest Patients
    216 Original Article Page 1 of 9 Surgical fixation of rib fractures decreases intensive care length of stay in flail chest patients Xiangzhi Xiao1#, Shengchao Zhang1#, Juhua Yang1, Jian Wang2, Zhilong Zhang2, Hao Chen1,2 1Department of Thoracic Surgery, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai 201700, China; 2Department of Thoracic Surgery, Xuhui Branch of Zhongshan Hospital, Fudan University, Shanghai 200031, China Contributions: (I) Conception and design: X Xiao, S Zhang, H Chen; (II) Administrative support: J Yang; (III) Provision of study materials or patients: X Xiao, S Zhang, J Yang, H Chen; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Hao Chen, MD, PhD. Department of Thoracic Surgery, Xuhui Branch of Zhongshan Hospital, Fudan University, 966 Middle Huaihai Road, Shanghai 200031, China. Email: [email protected]. Background: Nonoperative treatment is currently the standard therapy for rib fractures. However, there is a trend towards surgical fixation from conservative management over the last decade. While surgical fixation of rib fractures has shown promising results, its impact on the clinical results remains unclear based on the current literature. As such, the present study aims to compare the short-term outcomes of multiple rib fracture patients treated by surgical fixation with traditional conservative management. Methods: Data for patients with multiple (three or more) rib fractures admitted to our department between January 2012 and January 2019 were retrospectively collected and analyzed. Propensity score matched patients were compared between those treated with surgical rib fixation and those of nonoperatively treated.
    [Show full text]
  • NCI Designated Cancer Centers International Activities
    International Activities of NCI-Designated Cancer Centers Summary Report March 2014 This report is not a comprehensive summary of the international efforts of NCI-Designated Cancer Centers and not all of the efforts outlined in this report are NCI or NIH-funded. Rather, this report summarizes information that was provided by Cancer Centers who responded to requests from the NCI Center for Global Health for information on international activities. This is an ongoing data- collection effort, the data collection status for individual cancer centers can be found in Appendix A. Any additions or corrections are welcome. Please contact Rebecca Minneman ([email protected]). Table of Contents Abramson Cancer Center - University of Pennsylvania ....................................................................................4 Albert Einstein Cancer Center - Yeshiva University ..........................................................................................4 Alvin J. Siteman Cancer Center - Washington University ..................................................................................5 The Barbara Ann Karmanos Cancer Institute – Wayne State University ............................................................6 The Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA) ................................................................................................................................................... 10 Case Comprehensive Cancer Center - Case Western
    [Show full text]